Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Corcept Therapeutics’ SEC documents can feel like decoding a clinical protocol. The company’s filings overflow with data on glucocorticoid receptor trials, hypercortisolism patient outcomes, and R&D spend that shifts with every Phase 3 update—details investors can’t ignore yet rarely have time to dissect. Stock Titan’s AI turns these dense pages into clear takeaways, so “Corcept Therapeutics SEC filings explained simply” is more than a promise; it’s a deliverable.
Need the latest “Corcept Therapeutics quarterly earnings report 10-Q filing” or want to see how rising trial costs flow through cash burn? Our platform captures each 10-Q the moment it posts to EDGAR, then highlights revenue from Korlym, pipeline expense, and guidance shifts. The full annual report—think “Corcept Therapeutics annual report 10-K simplified”—is automatically condensed, surfacing FDA risk factors and licensing obligations in minutes. Prefer narrative? The earnings report filing analysis module answers searches like “Corcept Therapeutics earnings report filing analysis.” Sudden study read-outs? An “Corcept Therapeutics 8-K material events explained” panel pinpoints what changed and why. All of this exemplifies understanding Corcept Therapeutics SEC documents with AI.
Monitoring management sentiment? Real-time dashboards surface every “Corcept Therapeutics insider trading Form 4 transactions.” You’ll also find the exact phrase “Corcept Therapeutics Form 4 insider transactions real-time” already filtered by officer, option exercise, and date. Proxy statements reveal leadership incentives for anyone researching “Corcept Therapeutics proxy statement executive compensation.” Whether you’re tracking catalysts, benchmarking R&D efficiency, or following “Corcept Therapeutics executive stock transactions Form 4,” our AI-powered summaries, smart search, and export tools put the entire universe of Corcept Therapeutics filings within easy reach.
Corcept Therapeutics Inc. reported a Rule 144 notice for the proposed sale of 20,000 common shares through Stifel Nicolaus & Company Inc. on
The notice also discloses multiple sales by the same person, William Guyer, over the past three months: 4,379, 500, 14, 35,007, and 20,000 shares on dates from
Form 144 notice for Corcept Therapeutics, Inc. (CORT) reports a proposed sale of 40,000 common shares acquired by stock option exercise on 07/06/2022. The sale is to be effected through Stifel Nicolaus & Company Inc. on or about 10/01/2025 with an aggregate market value listed as $3,324,400. The filing shows the issuer's outstanding shares at 105,370,000. The seller appears in recent sale history as Joseph Belanoff, who sold 615 shares on 07/17/2025 for $45,318, 40,000 shares on 08/04/2025 for $2,742,006, and 40,000 shares on 09/02/2025 for $2,821,034. The filer certifies no undisclosed material nonpublic information and provides standard signature/representation language.
Corcept Therapeutics (CORT) insider filing under Rule 144 reports a proposed sale of 20,000 common shares through Stifel Nicolaus & Co., with an aggregate market value of $1,662,200 and an approximate sale date of 10/01/2025. The filing states the 20,000 shares were acquired via a stock option exercise and paid in cash on 10/01/2025. The filer also disclosed multiple prior open-market sales by the same person over the past three months totaling 62,000 shares with gross proceeds reported for each trade. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
CORCEPT THERAPEUTICS INC (CORT) Form 144 filing reports a proposed sale of 5,000 common shares through Stifel Nicolaus & Co. with an aggregate market value of $415,550.00, planned for 10/01/2025 on NASDAQ. The filing states these 5,000 shares were acquired the same day (10/01/2025) by stock option exercise and paid in cash.
The filing also lists prior sales by the same person, Joseph D. Lyon, totaling 15,000 shares sold on 07/01/2025, 07/17/2025, 07/18/2025, 08/01/2025, and 09/02/2025 with reported gross proceeds for each transaction. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported a transaction dated 09/19/2025. The Form 4 shows a disposition of 200 shares of Common Stock coded as G(1) at a price of $0, with an explanatory note that the shares were donated to a Fidelity Charitable Giving Account. Following the reported transaction, the reporting person beneficially owned 5,287 shares. The form is signed by an attorney-in-fact and cites a power of attorney on file with the SEC.
Gillian M. Cannon, a director of Corcept Therapeutics Inc. (CORT), reported a donation of 7,393 shares of the issuer's common stock executed on 09/10/2025 under transaction code G(1). The filing shows the shares were donated to a Fidelity Charitable Giving Account and the reporting person’s beneficial ownership of common stock following the transaction is reported as 0 shares. The Form 4 was signed by an attorney-in-fact, Joseph Douglas Lyon, on 09/11/2025. The filing includes a remark that the power of attorney is on file with the SEC.
Daniel N. Swisher Jr., a director of Corcept Therapeutics, executed transactions on 09/10/2025 under a 10b5-1 plan adopted August 1, 2024. He exercised 2,200 stock options with an exercise price of $14.08 and simultaneously sold the resulting 2,200 common shares at $72.45. Following the transactions, the Form 4 reports 0 shares of common stock beneficially owned from the sold shares. The filing also shows the exercised options were fully exercisable and references remaining derivative holdings totaling 3,300 (as reported in the derivative table). The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Form 144 notice for Corcept Therapeutics, Inc. (CORT) discloses a proposed sale of 2,200 common shares to be executed on 09/10/2025 through Fidelity Brokerage Services (NASDAQ). The filing lists an aggregate market value of $159,390 and reports 105,371,729 shares outstanding. The shares were acquired under an option granted 08/20/2018 and the reported payment method is cash. The filer, identified in past sales as Daniel Swisher, sold three prior blocks of 2,200 shares each on 06/10/2025, 07/10/2025 and 08/11/2025, with gross proceeds shown for each sale. Remarks and signature attestations are present but no additional explanatory text or plan-adoption date is provided.
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
